Symbiox Investment & Trading Co. Ltd.

221, Rabindra Sarani, 3rd Floor Room No. - 1, Kolkata - 700 007

Contact: 98302 74227 CIN: L65993WB1979PLC032012

Website: www.symbioxinvestment.com E-mail: symbioxinvestment100@gmail.com

Date: 12th November, 2024

To,
Compliance Department
Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th floor, Plot No C 62, G - Block,
Opp. Trident Hotel, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400 098

To, The Calcutta Stock Exchange Limited 7, Lyons Range, Kolkata- 700 001

To,

The Bombay Stock Exchange Limited, PJ Towers, Dalal Street Mumbai- 400 001

Subject: Outcome of Board Meeting held on 12th November, 2024.

BSE Scrip Code: 539278 CSE Scrip Code: 029461 Symbol: SYMBIOX

Dear Sir,

We would like to inform you that the Meeting of Board of Directors of M/s. Symbiox Investment & Trading Co Ltd was held on Tuesday, 12th November, 2024 at its registered office address to inter-alia transact the following matters:

- 1. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, approved the Unaudited Financial Results for the quarter and half year ended on 30th September, 2024.
- 2. Adopted Auditor's Limited Review Report given by Statutory Auditor of the Company for the quarter and half year ended on 30th September, 2024.
- 3. No other matters was transacted at the meeting.

Kindly note that the meeting of the Board of Directors commenced at 02:30 P.M and concluded at 04:10 P.M.

Please take the same on your record and acknowledge the receipt of the same.

Thanking You.

Yours Faithfully,

For Symbiox Investment & Trading Co Ltd

Khushboo Pitti
Company Secretary and Compliance Officer

SYMBIOX INVESTMENT & TRADING CO LTD

221, RABINDRA SARANI, 3RD FLOOR, ROOM NO-1, KOLKATA -700007

CIN - L65993WB1979PLC032012

Email - symbioxinvestment100@gmail.com; Website: www. symbioxinvestment.com

Satement of Unaudited Financial Result for the Quarter and Half year ended 30th Sept, 2024

(Rupees in Lakh except EPS)

[1	Quarter ended Half Year					
	Particulars						Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudite d	Unaudited	Audited
1	Revenue From Operations	75.16	31.23	123.22	106.39	259.37	389.79
	Other Income	0,00	0.00	3.00	0.00	14.51	23.00
	Total Income (I+II)	75.16	31,23	126.22	106.39	273.88	412.79
IV	EXPENSES						
	Cost of materials consumed		-	ı	0.00	0.00	0.00
	Purchases of Stock-in-Trade	30.72	47.24	30.83	77.96	210.13	335.64
	Changes in inventories of finished goods,		·				
	Stock-in -Trade and work-in-progress	√7 . 10	-34.76	68.67	-41.86	6.33	11.84
	Employee benefits expense	3.60	4.10	5.50	7.70	10.29	17.37
	Finance costs	0.00	0.00	0.00	0.00	0.00	0.00
	Depreciation and amortization expense	0.07	0.07	0.05	0.14	0.05	0.20
	Other expenses	3.65	13.83	3.46	17.48	14.02	22.99
	Total expenses (IV)	30,94	30.48	108.51	61.42	240.82	388.04
	Profit/(loss) before exceptional items and					***************************************	
V	tax (I- IV)	44.22	0.75	17.71	44.97	33.06	24.75
VI	Exceptional Items			-			0.00
	Profit/(loss) before tax						
VII	(V-VI)	44:22	0.75	17.71	44.97	33.06	24.75
VIII	Tax expense:						
	(1) Current tax	11,50	0.19	4.59	11.69	8.59	3.93
	(2) Deferred tax		-	-		0.00	0.00
	Profit (Loss) for the period from					·	
ΙX	continuing operations (VII-VIII)	32.72	0.56	13.12	33.28	24.47	20.82
Х	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
ΧI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
	Profit/(loss) from Discontinued operations						
XII	(after tax) (X-XI)	32,72	0.56	13.12	33.28	24.47	20.82
XIII	Profit/(loss) for the period (IX+XII)	32,72	0.56	13.12	33.28	24.47	20.82
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to						
	profit or loss		-	-	-	-	
	(ii) Income tax relating to items that will						
	not be reclassified to profit or loss		-	₩.	-	-	-



	B (i) Items that will be reclassified to						
	profit or loss		-		-	-	-
	(ii) Income tax relating to items that will						
	be reclassified to profit or loss		-	-		-	~
	Total Comprehensive Income for the						
	period (XIII+XIV)(Comprising Profit		i				
	(Loss) and Other Comprehensive Income						
XV	for the period)	-	-			-	
	Paid up equity share Capital (No. of Shares)	31287330	31287330	31287330	31287330	31287330	31287330
	Face Value	10.00	10.00	10.00	10.00	10.00	10.00
	Earnings per equity share (for continuing	10.00	10.00	20.00	10.00	10.00	10.00
XVI	operation):						;
	(1) Basic	0.105	0.0018	0.042	0.106	0.078	0.067
	(2) Diluted	0.105	0.0018	0.042	0.106	0.078	O.067
XVII	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.000	0.000	0.000	0.000	0.000	0.000
	(2) Diluted	0.000	0.000	0.000	0.000	0.000	0.000
XVIII	Earnings per equity share(for discontinued & continuing operations)						
	(1) Basic	0.000	0.000	0.000	0.000	0.000	0.000
	(2) Diluted	0.000	0.000	0.000	0.000	0.000	0.000

M	ot	Δ

- The above Unaudited financial results were reviewed by Audit Committee and approved by the Board of Directors in their meeting held on 12th November, 2024.
- 2 The previous period figures have been regrouped wherever necessary.
- The Statutory auditors of the Company have carried out a "Auditor's report" of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.
- The Company has adopted Indian Accounting standards (Ind AS) with effect from 01st April, 2017 and accordingly, the above results have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013
- The above results for the quarter & half year ended 30th Sept.,2024 along with Auditor Report has been approved by the Board of Directors of the Company.
- There are no qualofication in the Audit Report issued by the Auditor

For and behalf of Board SYMBIOX INVESTMENT & TRADING: CO LTD

Place: Kolkata Date: 12.11.2024 Samit Ray Managing Director DIN No.08406285

SYMBIOX INVESTMENT & TRADING CO LTD

221, RABINDRA SARANI, 3RD FLOOR, ROOM NO-1, KOLKATA -700007

CIN - L65993WB1979PLC032012

Email - symbioxinvestment100@gmail.com

Statement of Assets and Liabilities for Company

(Rs, in Lakh)

	StandaloneStatement of Assets and Liabilities	As at 30th Sept 2024	As at 31st March 2024
	Particulars	(Unaudited)	(Audited)
Α	ASSEST		
1	Non-current assets		
	(a) Property, plant and equiptment	1.66	1.81
	(b) Capital work-in -progress		-
	(C) Goodwill	•	
	(c) other Intengible assets	-	-
	(d) Intengible assets under development	-	*
	(e) Investments in subsidiary, joint ventures and associate	-	-
	(f) Non- current Financial Assets	-	_
	(i) Non-current investments	-	-
	(ii) Non-current Trade receivables	-	-
	(iii) Non-current Loans	_	-
	(iv) Other Non-current financial assests	_	
	Total non-current financial assets	1.66	1.81
	(g) Defferred tax assets (net)	_	_
	(h) Other non-current assets	-	-
	Total non-current assets	1.66	1.81
2	Current Assets		
	(a) Inventories	50.82	8.96
	(b) Current financial assets	•	-
	(i) Current Investments	1,099.46	987.85
	(ii) Trade receivables	55.33	1.54
	(iii) Cash and cash equivalents	1 1 .44	4.61
	(iv) Bank Balance other than cash and cahs equivalents	0.78	26.58
	(v) Current Loans	1,961.44	2,143.02
	(vi) Other corrent financial assets	21.93	9.29
	Total current financial assets	3,201.20	3,181.85
	(c) Current tax assets (net)	_	-
	(d) Other current financial assets	<u>-</u>	-
	Total Current assets	3,201.20	3,181.85
- 1	Non-current assets classified as held for sale Regulatory deferral account debit balance and related deferred tax Assets		
٦	Total Assets	3,202.86	2 102 66
١	Total Assets	3,202.86	3,183.66



В	EQUITY AND LIABILITIES		
1	EQUITY		
	Equity attributable to owner of parent	_	79
	(a) Equity share Capital	3,128.73	3,128.73
	(b) Other equity	57.75	24.48
	Total Equity attributable to owner of parent	3,186.48	3,153.21
	(c) Non controlling interest	-	_
	Total Equity	3,186.48	3,153.21
2	LIABILITIES		
	Non-current liabilites		
]	(a) Non-current financial liabilites		
	(i) Borrowings	No.	-
	(ii) Trade Payables	-	-
	(iii) Other non-current financial liabilities	-	-
	Total non-current liabilities		-
	(b) Provisions	<u>=</u>	-
	(c) Deferred tax liabilities (net)	-	-
	(d) Deferred government grants	-	<u>-</u> .
	(e) Other non-current liabilities	_	
	Total non-current liabilities		-
3	Current liabilities		-
	(a) Current Financial liabilities		
	(i) Borrowings		
	(ii) Trade paybles	0.64	20.22
	(iii) Other current financial liabilities	-	-
	Total current financial liabilities	0.64	20.22
	(b) Other current liabilited	0.12	6.31
	(c) provisions	15.62	3.92
	(e) Current tax liabilities (Net)	~	-
	(f) Deferred government grants	-	· •
	Total current libilities	15.74	10.23
	Liabilities directly associated with assets in disposal group		
4	classied as held for sale		
	Regulatory deferral account credit balance and related deferred		
5	tax libility		_
	Total liabilities	16.38	30.45
Į	Total Equity and Liabilities	3,202.86	3,183.66

For and behalf of Board SYMBIOX INVESTMENT & TRADING CO.LTD

Place: Kolkata

Date: 12.11.2024

Samit Ray
Managing Director

DIN No.08406285

SYMBIOX INVESTMENT & TRADING CO LTD

L65993WB1979PLC032012

CASH FLOW STATEMENT FOR THE PERIOD ENDED ON 30TH SEPT., 2024

	For the year ended	For the year ended
	30th Sept. 2024	31st March 2024
	(Rupees in lakh)	(Rupees in lakh)
CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before tax and after extra- ordinary	44.97	24,75
items (As per profit & loss account)	0.15	0.2
Adjustments for items not included		
Operating Profit before working capital changes	45.12	24.9
Working capital adjustments: -		
(Increase)/ decrease in current loans and advances	181.58	-301.30
(Increase)/ decrease in Inventories	-41.86	11.8
(Increase)/ decrease in Trade receivables	-53.79	78.20
(Increase)/ decrease in current assets	-12.64	-2.05
Increase/ (decrease) in Trade Payable	-19.58	-106.99
Increase/ (decrease) in current liabilities	-6.19	-4.7
Cash generated from operations	92.64	-300.12
Direct Taxes Paid(Net of refund)	-	5.64
Net cash flow from operating activities (A)	92.64	-305.76
CASH FLOW FROM INVESTING ACTIVITIES		
Proceed from sale(purchase) of investments	-111.61	284.38
(Increase)/decrease in capital expenditure		•
(Increase)/decrease in fixed assets		-1.64
Net cash flow from investing activities (B)	-111.61	282.74
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of equity shares		
Share Applocation Money received(refund)	,	**
Net cash flow from financing activities (C)	-	-
Net cash flow during the year (A + B + C)	-18.97	-23.02
Add: Opening cash and cash equivalents	31.19	54.21
Closing cash and cash equivalents	12,22	31.19
Components of cash and cash equivalents		
Cash in hand	11.44	4.61
Deposit with banks in current accounts	0.78	26.58
Toal cash and cash equivalents	12.22	31.19

For and behalf of Board SYMBIOX INVESTMENT & TRADING CO LTD.

Place: Kolkata Date: 12.11.2024

Managing Director



SSRV & Associates

Chartered Accountants

Independent Auditors' Limited Review Report on quarterly and half yearly unaudited standalone financial results of Symbiox Investment & Trading Co Ltd pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to
The Board of Directors.

Symbiox Investment & Trading Co Ltd
221, Rabindra Sarani, 3rd Floor
Room No. 1, Kolkata-700007

- 1. We have reviewed the accompanying statement of unaudited financial results of **Symbiox Investment & Trading Co Ltd** ('the Company') for the quarter and half year ended September 30, 2024 (the "Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements') Regulations, 2015.
- 2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 1. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Including the manner in which it is to be disclosed, or that it contains any material misstatement

For S S R V & Associates

Chartered Accountants

Firm Reg No: 135901

Vishnu Kant Kabi

Partner

Membership No. 403437 Date: 12th November, 2024

Place: Mumbai

UDIN: 24403437BKALBM9848